
Temple Wearable Controversy Exposes India's Validation Gap
Temple's BrainFlow studies rest on 23 subjects and await peer review, while founders reveal a ₹15 Lakh cost per 100-person trial and a 16-month CDSCO approval road.
- By
- Rebecca Stone
- Filed
- Channel
- Consumer Tech
- Read
- 5 min read
Deepinder Goyal's Temple launched with two proprietary physiological metrics — BrainFlow and Entropy — validated so far by studies involving as few as 23 healthy adults, both still listed as under peer review. That gap, and the regulatory fog around it, is what India's wearable industry is really fighting over on X this month.
The battle over Temple has been heated and loud. But the shouting has skipped a harder question: what does it actually take to launch a health-tracking wearable built in India, and who checks the numbers?
"There is no established playbook for making wearables in India. If you have the capital, you can set up a team, hire a bunch of researchers and scientists and come up with a product and even start selling it," a California-based Indian founder of a wearable startup told Inc42.
That's the impasse. Manufacturers can sell devices that track physiological parameters in India without the clinical validation expected of medical devices.
What Is Temple Actually Measuring?
Temple, which Goyal launched after his Continue research work on the Gravity Aging Hypothesis, promises two new metrics. BrainFlow reportedly tracks relative changes in blood flow to the brain during everyday activity. Goyal has described Entropy as a measure of how hard the body works to shed heat, capturing load across thermal, immune, digestive, cognitive and other systems.
There's a catch. Temple's own research papers state the device cannot directly measure cerebral blood flow. In response to Inc42's questions, the company said the Brain Flow Index is a relative index derived from optical signals collected at the temple, and that it rose and fell alongside blood-flow velocity in the middle cerebral artery as measured by transcranial Doppler ultrasound.
The index currently does two things in Temple's fitness app: it lets users compare cardio-session intensity, and it sends prompts to move when the index drops during long sitting periods.
Heart rate and sleep tracking rest on algorithms refined over years. New biomarkers don't.
"The real work comes when you develop a new tracker or establish a new biomarker or a new benchmark for measuring something new," the first founder said. Specialised algorithms need research papers and validation — which is why much of the medical fraternity remains sceptical.
Temple's research page lists a 23-person study comparing BrainFlow against transcranial Doppler, plus another against near infrared spectroscopy (NIRS). Both are under peer review. A spokesperson said validation work on Entropy is in its final stages, with findings to be published soon. The company says it has partnered with academic institutions worldwide on larger, more diverse studies.
Why Peer Review vs. Preprint Matters
On November 8, Goyal acknowledged the gap between peer review, the studies and the device launch, and said BrainFlow was the starting point for Temple's research, not its primary proposition. In a November 5 post, he said preprints would precede peer-reviewed publication, with validation continuing as the product reached users.
A white paper or preprint opens research to public scrutiny. Peer review adds independent assessment of methodology, findings and conclusions.
"Generally, you need a double-blind test, a control group and a placebo group. The bare minimum that is respectable enough is 90 people," a second founder, building neuro-centric wearables, told Inc42. On whether 23 subjects suffice: "You can do it for 10 people. Nothing is a mandate. But is it respectable to have a big test group? Maybe."
Nothing compels startups to publish research at all. "It's not necessary to put out your research papers, but it is something that people demand for credibility," the founder said. "Third-party trials are what most wearables get asked for, by investors and consumers. Even doctors are asking for them."
Cost is the choke point. The second founder's startup spent roughly ₹15 Lakh on a 100-subject study — steep at the early stage, when most raised funds are already depleted by the time testing begins.
Is Temple a Medical Device?
Under the Medical Devices Rules, 2017, classification hinges on intended purpose and function. The Central Drugs Standard Control Organisation (CDSCO) regulates devices meant to diagnose, prevent, monitor or treat disease, or to investigate or modify physiological processes. Marketing language alone — "wellness tracker" — doesn't settle it.
Sceptical doctors have called for Temple to come under medical regulators. Goyal has repeatedly said Temple is not a medical device and doesn't diagnose or prevent disease. The company cited CDSCO's 2026 guidance on medical-device software, which excludes general-wellness software that makes no reference to disease. Temple says it will seek CDSCO approval before shipping any future medical-purpose feature.
What Does Regulation Cost in Practice?
The second founder's company obtained CDSCO approval despite making no medical claims, because it builds a brain-focused wearable. "In India, any brain wearable device needs CDSCO approval. Whether it is tracking blood flow or not," they claimed — though CDSCO's 2026 guidance sets no blanket brain-wearable requirement.
That clearance ran about 16 months, from November 2024 to March 2026. Before approval, companies may test only a CDSCO-determined number of units in India, which limits iteration.
Enforcement is uneven. "The CDSCO is not very active in looking into such companies, unfortunately. This is a loophole in India that many exploit," the founder said. A third founder put it bluntly: "The only reason we never say that it is a medical device is that compliance becomes very hard. Especially for a new startup." They also flagged mandatory Wireless Planning and Coordination (WPC) and Bureau of Indian Standards (BIS) certifications, alongside FCC and Bluetooth Low Energy certification for products sold in the US. Temple says it holds all certifications required in markets where it sells, without specifying them.
Can Temple Build the Missing Playbook?
Founders credit the temple placement as sound engineering — an accessible site for optical sensing — while cautioning that measuring blood flow at the temple doesn't prove measurement within the brain. Goyal has committed substantial personal capital, and senior founders and investors point to his Zomato and Blinkit record.
In his November 8 post, he told consumers they were free to wait for peer-reviewed evidence, and promised a detailed explanation of how BrainFlow is calculated, its applications and its limitations. As manufacturers move beyond steps, sleep and heart rate toward new physiological benchmarks, they will have to show what the numbers mean — and Temple's scientific claims will need to withstand independent scrutiny before consumers can judge what the device delivers.
Source: inc42.com
More from Rebecca Stone
Show full bio
Correspondent covering technology and product news in Semiconductors, chip manufacturing, hardware, AI compute at Chip Dispatch.
985 articles
Related articles
deepinder-goyal-defends-temple-wearable-cites-30-mn-spent-on-r-d
Deepinder Goyal Defends Temple Wearable, Cites $30 Mn Spent on R&D
hiyd-builds-7-gram-health-sensor-that-mounts-on-existing-watches-9bd36ca8
Hiyd Builds 7-Gram Health Sensor That Mounts on Existing Watches
google-prices-fitbit-air-at-13-999-in-india-47-above-us-price-b6034f97
Google Prices Fitbit Air at ₹13,999 in India — 47% Above US Price


